Evidence map›Paper›PMID 36857009›Full record

ArticleEndocrine2023

Long-term cardiometabolic morbidity in young adults with classic 21-hydroxylase deficiency congenital adrenal hyperplasia.

Beatrice Righi, Salma R Ali, Jillian Bryce, Jeremy W Tomlinson, Walter Bonfig, Federico Baronio, Eduardo C Costa, Guilherme Guaragna-Filho, Guy T'Sjoen, Martine Cools and 12 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Endocrine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 15 institutions in 10 countries.

Beatrice RighiDevelopmental Endocrinology Research Group, University of Glasgow, Royal Hospital For Sick Children, Glasgow, UK. beatrice.righi2406@gmail.com.ORCID 0000-0003-4084-1077
Salma R AliDevelopmental Endocrinology Research Group, University of Glasgow, Royal Hospital For Sick Children, Glasgow, UK.
Jillian BryceOffice for Rare Conditions, Royal Hospital for Children & Queen Elizabeth University Hospital, Glasgow, UK.
Jeremy W TomlinsonOxford Centre for Diabetes, Endocrinology & Metabolism, NIHR Oxford Biomedical Research Centre, Churchill Hospital, University of Oxford, Oxford, UK.
Walter BonfigDepartment of Paediatrics, Technical University München, Munich, Germany.
Federico BaronioPediatric Unit, Department Hospital of Woman And Child, IRCSS S.Orsola-Malpighi University Hospital, Bologna, Italy.
Eduardo C CostaPediatric Surgery Service, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.
Guilherme Guaragna-FilhoDepartment of Pediatrics, School of Medicine, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, Brazil.
Guy T'SjoenDepartment of Endocrinology - Center for Sexology and Gender, Ghent University Hospital, Ghent, Belgium.
Martine CoolsDepartment of Internal Medicine and Paediatrics, Ghent University and Department of Pediatric Endocrinology, Ghent University Hospital, Ghent, Belgium.
Renata MarkosyanEndocrinology, Yerevan State Medical University Endocrinology Clinic, Yerevan, Armenia.
Tania A S S BachegaUnidade de Endocrinologia do Desenvolvimento, Laboratório de Hormônios e Genética Molecular/LIM42, Disciplina de Endocrinologia, Hospital Das Clinicas, Faculdade De Medicina, Universidade de Sao Paulo, São Paulo, Brazil.
Mirela C MirandaUnidade de Endocrinologia do Desenvolvimento, Laboratório de Hormônios e Genética Molecular/LIM42, Disciplina de Endocrinologia, Hospital Das Clinicas, Faculdade De Medicina, Universidade de Sao Paulo, São Paulo, Brazil.
Violeta IotovaUMHAT Sveta Marina, Medical University of Varna, Varna, Bulgaria.
Henrik FalhammarDepartment of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
Filippo CeccatoEndocrinology Unit, Department of Medicine DIMED, University-Hospital of Padua, Padua, Italy.
Marianna R StancampianoDepartment of Pediatrics, Endocrine Unit, IRCCS San Raffaele Scientific Institute, Endo-ERN Center for Rare Endocrine Conditions, Milan, Italy.
Gianni RussoDepartment of Pediatrics, Endocrine Unit, IRCCS San Raffaele Scientific Institute, Endo-ERN Center for Rare Endocrine Conditions, Milan, Italy.
Eleni DanielDepartment of Oncology and Metabolism, University of Sheffield, Sheffield, UK.
Richard J AuchusDivision of Metabolism, Endocrinology and Diabetes, University of Michigan, Ann Arbor, MI, USA.
Richard J RossDepartment of Oncology and Metabolism, University of Sheffield, Sheffield, UK.
S Faisal AhmedDevelopmental Endocrinology Research Group, University of Glasgow, Royal Hospital For Sick Children, Glasgow, UK.
Royal Hospital for Children · GBGhent University Hospital · BEHospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo · BRUniversity of Sheffield · GBVita-Salute San Raffaele University · ITChurchill Hospital · GBHospital de Clínicas de Porto Alegre · BRIRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola · ITKarolinska University Hospital · SEKlinikum Wels-Grieskirchen · ATMedical University of Varna · BGUniversidade Federal do Rio Grande do Sul · BRUniversity of Michigan · USUniversity of Padua · ITYerevan State Medical University · AM

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo study the current practice for assessing comorbidity in adults with 21-hydroxylase CAH and to assess the prevalence of comorbidity in these adults.

methodsA structured questionnaire was sent to 46 expert centres managing adults with CAH. Information collected included current therapy and surveillance practice with a particular focus on osteoporosis/osteopaenia, hyperlipidaemia, type 2 diabetes/hyperinsulinaemia, hypertension, CV disease, obesity.

resultsOf the 31 (67%) centres from 15 countries that completed the survey, 30 (97%) screened for hypertension by measuring blood pressure, 30 (97%) screened for obesity, 26 (84%) screened for abnormal glucose homoeostasis mainly by using Hb1Ac (73%), 25 (81%) screened for osteoporosis mainly by DXA (92%), 20 (65%) screened for hyperlipidaemia and 6 (19%) screened for additional CV disease. Of the 31 centres, 13 provided further information on the six co-morbidities in 244 patients with a median age of 33 yrs (range 19, 94). Of these, 126 (52%) were females and 174 (71%) received fludrocortisone in addition to glucocorticoids. Of the 244 adults, 73 (30%) were treated for at least one comorbidity and 15 (21%) for more than 2 co-morbidities. Of 73, the patients who were treated for osteoporosis/osteopaenia, hyperlipidaemia, type 2 diabetes/hyperinsulinaemia, hypertension, CV disease, obesity were 43 (59%), 17 (23%), 16 (22%), 10 (14%), 8 (11), 3 (4%) respectively.

conclusionCardiometabolic and bone morbidities are not uncommon in adults with CAH. There is a need to standardise the screening for these morbidities from early adulthood and to explore optimal therapy through routine collection of standardised data.

Indexed as

Adrenal Hyperplasia, CongenitalCardiovascular DiseasesDiabetes Mellitus, Type 2HyperinsulinismHypertensionOsteoporosisAdultFemaleHumansMaleObesityPrevalenceYoung Adult21-hydroxylase deficiencyCo-morbiditiesCongenital adrenal hyperplasiaOutcomeRegistry

Identifiers

PMID36857009
PMCPMC10199864
OpenAlexW3199318628

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.